India, Feb. 26 -- Digital medicine company, Akili, Inc. (AKLI), Monday announced positive results for Phase 3 of SDT-001, a localised version of endeavorRx, conducted by its Japanese partner Shionogi & Co. Ltd. for the treatment of pediatric ADHD patients aged 8 to 17 years.
EndeavorRx had been earlier approved by the U.S. Food and Drug Administration or FDA as the world's first prescription digital therapeutic for pediatric patients with primarily inattentive or combined-type ADHD.
Shionogi's trial intended to evaluate the efficacy and safety of SDT-001, achieved its primary endpoint successfully with symptom improvements noticed after two cycles of usage.
The company said that the outcome has made it a step closer to making the product...